Clinical Trial Update: A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the effects of a 5 mg zoledronic acid infusion on bone mineral density in postmenopausal osteoporosis patients aged 50–65 has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: COMPLETED